Keto Diet and Glioblastoma: 2026 Clinical Trial Update
Two major developments in 2026 are pushing keto into serious oncology research: a Phase II randomised trial at UCSF testing keto as an adjuvant to standard glioblastoma treatment, and a systematic review of all available clinical evidence published in a peer-reviewed journal. Glioblastoma remains one of the most aggressive cancers, with a median survival of just 12 to 15 months despite standard chemoradiation. The UCSF Diet2Treat study is enrolling 170 newly diagnosed patients across multiple sites, randomising them 1:1 to an 18-week ketogenic protocol or standard dietary guidance alongside chemoradiotherapy. Early data suggests the diet is feasible and well tolerated in this fragile population, but survival benefits remain to be confirmed, with full results expected from 2027 onward.
Why researchers think keto could starve brain tumours
Glioblastoma cells are highly dependent on glucose for energy. The ketogenic diet dramatically reduces circulating glucose while raising ketone bodies. Because tumour cells have impaired mitochondria and cannot efficiently use ketones, researchers hypothesise that keto creates a metabolic environment that is selectively unfavourable for tumour growth. Healthy neurons, by contrast, can adapt and run efficiently on ketones. This Warburg-effect-based reasoning has driven interest in keto as a complementary cancer strategy for over a decade.
The UCSF Diet2Treat Phase II trial
UCSF's Brain Tumor Center is conducting a multi-site, randomised Phase II study enrolling 170 patients with newly diagnosed glioblastoma. Participants are randomised 1:1 to either an 18-week ketogenic diet or standard anti-cancer dietary guidance, both alongside standard radiotherapy and chemotherapy. The primary endpoint is overall survival; time to tumour recurrence is assessed as a secondary outcome. The trial is open to patients who have not yet started treatment, and trained research dietitians supervise the intervention. Full results are not expected until 2027.
December 2025 systematic review: what the evidence says so far
A systematic review published in December 2025 in Medical Oncology analysed all available clinical trials on ketogenic metabolic therapy as an adjuvant for glioblastoma. The authors found that the diet is generally safe and clinically tolerable when used alongside standard-of-care treatment. Several smaller phase I studies, including one published in Nature's Scientific Reports in 2025, confirmed feasibility. However, the reviewers cautioned that none of the existing studies were large enough or long enough to demonstrate a statistically significant survival benefit. They called for more adequately powered randomised controlled trials before keto can be recommended as an evidence-based adjuvant therapy.
Safety and tolerability for cancer patients
One of the key concerns about adding a restrictive diet to an already demanding cancer treatment regimen is patient wellbeing. A clinical study published in early 2025 in Frontiers in Nutrition reported that selected glioblastoma patients were able to maintain ketosis throughout treatment without serious adverse events. Weight management was cited as a challenge, as cancer-related cachexia can worsen on a calorie-restricted version of keto. The trial teams monitored participants closely for nutritional adequacy and adjusted the protocol to preserve lean mass. These results support the feasibility of keto as an adjuvant, but highlight the need for specialised dietitian support.
What patients and clinicians should know now
Keto is not yet a standard-of-care recommendation for any cancer type, including glioblastoma. Major oncology bodies continue to defer formal guidance until Phase III evidence is available. Patients interested in trying a ketogenic diet during glioblastoma treatment should only do so within the framework of a clinical trial or under close supervision by both an oncologist and a registered dietitian. Self-directed keto during cancer treatment carries real risks of undernutrition and drug-nutrient interactions. Participation in trials like UCSF's Diet2Treat is the safest and most scientifically valuable way to explore this approach.
FAQ
Does the ketogenic diet cure glioblastoma?
No. There is currently no clinical evidence that a ketogenic diet cures glioblastoma. Ongoing Phase II trials are testing whether it can extend survival or delay recurrence when added to standard treatment. Results from adequately powered trials are expected in 2027 and beyond. Patients should always follow their oncologist's treatment plan.
How does keto affect cancer cells differently from healthy cells?
Cancer cells, including glioblastoma cells, typically rely heavily on glucose and cannot efficiently use ketones for energy due to mitochondrial dysfunction. Healthy neurons can adapt to burning ketones. This metabolic difference is the basis of the hypothesis that keto may selectively stress tumour cells. However, this mechanism has been primarily demonstrated in laboratory and animal studies; human clinical evidence is still limited.
Can I start keto during cancer treatment without a doctor's supervision?
No. Starting a ketogenic diet during active cancer treatment without medical supervision is not recommended. Cancer treatment already places significant metabolic stress on the body, and a poorly managed keto diet can lead to muscle loss, malnutrition, and interference with medications. Always consult your oncologist and a registered dietitian before making dietary changes during treatment.